COMP <GO>
GYRE vs LLY // 10Y YIELD & FRED MACRO BETA
Gyre Therapeutics Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: GYRE 2
— LLY 11
■ METRIC PARITY
LAST: $6.41 (-9.59%) • MKT CAP: $714.8M
macro-sensitivity
—
LAST: $1,373.70 (+6.63%) • MKT CAP: $1.29T
macro-sensitivity
0.51
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 95.40% | 83.64% | +11.76 | GYRE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | 32.36% | -6.96 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | 36.4x | +16.88 | LLY | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | 2.30% | -2.33 | LLY | /fcf-yield <GO> |
| Operating Margin | 9.90% | 40.21% | -30.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 31.90% | -23.40 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | 45.51% | -35.31 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 9.29 | +5.04 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 6.77% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 66.6 | -16.80 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | — | 0.51 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | 30.6x | +36.58 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $714.8M | $1.29T | -$1.29T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | LLY REV | GYRE GROSS % | LLY GROSS % | GYRE FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $65.18B | 95.4% | 83.0% | -$180.0K | $16.81B |
| FY 2024 | $105.8M | $45.04B | 96.3% | 81.3% | -$6.0M | $8.82B |
| FY 2023 | $113.5M | $34.12B | — | 79.3% | $25.9M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
LLY // BETA 0.51